Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1 Neoplasms 1 Diabetes Mellitus, Type 2 1

Interventions

Gemcitabine 19 130-nm albumin-bound paclitaxel 16 Specimen Handling 15 Irinotecan 11 Magnetic Resonance Spectroscopy 10 Fluorouracil 10 Leucovorin 9 Biopsy 9 Oxaliplatin 8 pembrolizumab 7 Cyclophosphamide 7 fludarabine 6 Cisplatin 5 Pemetrexed 4 Cetuximab 4 Albumin-Bound Paclitaxel 4 zimberelimab 3 trastuzumab deruxtecan 3 olaparib 3 irinotecan sucrosofate 3 durvalumab 3 dehydroftorafur 3 aldesleukin 3 Taxes 3 Radiosurgery 3 Nivolumab 3 Immunoglobulin G 3 Disulfides 3 Carboplatin 3 veliparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × Insulin × 30 days × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡